Shionogi Completes $2 Billion IntraBio Acquisition

Shionogi has completed its $2 billion acquisition of IntraBio, adding the rare-disease treatment AQNEURSA and IntraBio’s development and commercialization capabilities to its global portfolio.

Shionogi acquired all outstanding IntraBio shares through its New Jersey-based subsidiary. The transaction includes worldwide intellectual property and commercialization rights for AQNEURSA.

Expanding The Rare-Disease Portfolio

AQNEURSA is approved in the United States and Europe for certain neurological manifestations of Niemann-Pick disease type C.

The U.S. approval covers adults and pediatric patients weighing at least 15 kilograms. In Europe, it is authorized for adults and children aged six and older who weigh at least 20 kilograms, either with miglustat or as a standalone treatment when miglustat cannot be tolerated.

In September 2026, the U.S. Food and Drug Administration also approved AQNEURSA as the first treatment targeting ataxia in adults and pediatric patients diagnosed with Ataxia-Telangiectasia who weigh at least 15 kilograms.

The therapy is under European regulatory review for Ataxia-Telangiectasia. It is also being evaluated in a Phase 3 study for CACNA1A-related disorders.

Shionogi plans to continue the clinical programs started by IntraBio and examine the therapy’s potential in additional rare diseases.

Building Global Capabilities

The transaction follows Shionogi’s acquisition of RADICAVA ORS, a treatment for amyotrophic lateral sclerosis. The company said these additions have helped establish a commercial and medical-affairs foundation in rare and neurodegenerative diseases.

Shionogi’s pipeline also includes clinical programs involving Pompe disease, Fragile X syndrome, Jordan’s syndrome, and other rare neurodegenerative conditions.

KEY QUOTES:

With the closing of the IntraBio acquisition, we welcome AQNEURSA to Shionogi’s growing portfolio and strengthen our global capabilities with additional rare disease expertise. For nearly 150 years, Shionogi has grown our business by adapting to the changing needs of patients. This milestone is the latest representation of our steadfast commitment to deliver innovative medicines to protect the health and wellbeing of the patients we serve.

Isao Teshirogi, CEO of Shionogi

Through acquisitions, integrations and strategic hires, Shionogi is building a strong, sustainable rare disease presence with a clear purpose: to make a meaningful difference for patients. We have the infrastructure, portfolio, and commitment to deliver the medicines, patient support and services, and the scientific expertise and determination to advance new treatment options for tomorrow.

Nathan McCutcheon, President and CEO of Shionogi Inc.

We look forward to partnering with patient groups representing people living with these devastating conditions, and learning from patients, families and carers about the challenges they face and how we can best help improve their lives.

Huw Tippett, CEO of Shionogi Europe

We look forward to partnering with the Shionogi team. The recent U.S. regulatory approval of AQNEURSA, the first targeted treatment for A-T, has brought hope to many children and their families. With the additional reach and resources that Shionogi brings, we are hopeful that more A-T families will be able to access this treatment.

Brad Margus, Founder of A-T Children’s Project

For the Niemann-Pick community, this acquisition is an opportunity to build on progress to date for people living with NPC and their families. We are deeply grateful to IntraBio for securing approval for AQNEURSA and their support of our community. We look forward to working with Shionogi to expand access and ensure this important therapy reaches the families who need it most.

Heather Teal, Executive Director of the National Niemann-Pick Disease Foundation